What is Sarcoma?

Posts Tagged ‘Leiomyosarcoma’

What is Sarcoma?

Sarcoma is a rare type of cancer and typically produces malignant tumors derived from the connective tissue.  There are more than 70 sarcoma types and subtypes. Soft Tissue Sarcoma Soft tissue sarcoma broadly defines cancers that develop in the body’s soft tissues (i.e. muscles, tendons, fat, lymph vessels, blood vessels, and nerves). While these cancers are most commonly found in the head, neck, arms, legs, chest, and abdomen, they can develop anywhere in the body. There are various different types of soft tissue sarcoma, and depending on the type of soft tissue the cancer started in, the cells will look…  Read More »

Sarcoma Foundation of America Announces New Grant Awards for Uterine Leiomyosarcoma Research

DAMASCUS, Md. – November 1, 2018 – The Sarcoma Foundation of America (SFA), the leading organization dedicated to increased research and awareness for sarcoma, today announced two research grants awarded to projects focused on the study of uterine leiomyosarcoma.  Uterine leiomyosarcoma is a rare subtype of sarcoma, a cancer that occurs in soft tissue and bone. Made possible by the generosity of the Dr. Richard and Valerie Aronsohn Memorial Fund, these awards support investigative efforts by leading sarcoma researchers at Memorial Sloan-Kettering Cancer Center and Stanford University. These research projects are eligible for renewal, potentially bringing the SFA’s overall investment…  Read More »

Sarcoma Foundation of America Applauds FDA Approval of Yondelis

-Drug Approved for Use in Treatment of Advanced Liposarcoma and Leiomyosarcoma- DAMASCUS, Md. – October 23, 2015 – The Sarcoma Foundation of America (SFA) applauds the announcement by the Food and Drug Administration (FDA) that the drug Yondelis (trabectedin, marketed by Janssen) has been approved by the agency for the treatment of advanced liposarcoma and leiomyosarcoma, two subtypes of soft tissue sarcoma. Yondelis has received approval for the use in the treatment of patients with unresectable or metastatic liposarcoma and leiomyosarcoma who have previously received an anthracycline chemotherapy. “The Sarcoma Foundation of America is thrilled with the FDA’s decision to approve…  Read More »